Cargando…

Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors

The cochaperone CDC37 promotes association of HSP90 with the protein kinase subset of client proteins to maintain their stability and signalling functions. HSP90 inhibitors induce depletion of clients, which include several oncogenic kinases. We hypothesised that the targeting of CDC37 using siRNAs...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Jennifer R., Clarke, Paul A., de Billy, Emmanuel, Workman, Paul
Formato: Texto
Lenguaje:English
Publicado: 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635547/
https://www.ncbi.nlm.nih.gov/pubmed/18931700
http://dx.doi.org/10.1038/onc.2008.380
_version_ 1782164189373005824
author Smith, Jennifer R.
Clarke, Paul A.
de Billy, Emmanuel
Workman, Paul
author_facet Smith, Jennifer R.
Clarke, Paul A.
de Billy, Emmanuel
Workman, Paul
author_sort Smith, Jennifer R.
collection PubMed
description The cochaperone CDC37 promotes association of HSP90 with the protein kinase subset of client proteins to maintain their stability and signalling functions. HSP90 inhibitors induce depletion of clients, which include several oncogenic kinases. We hypothesised that the targeting of CDC37 using siRNAs would compromise the maturation of these clients and increase the sensitivity of cancer cells to HSP90 inhibitors. Here we show that silencing of CDC37 in human colon cancer cells diminished association of kinase clients with HSP90 and reduced levels of the clients ERBB2, CRAF, CDK4 and CDK6, as well as phosphorylated AKT. CDC37 silencing promoted the proteasome-mediated degradation of kinase clients, suggesting a degradation pathway independent from HSP90 binding. Decreased cell signalling through kinase clients was also demonstrated by reduced phosphorylation of downstream substrates and colon cancer cell proliferation was subsequently reduced by inhibition of the G1/S-phase transition. Furthermore, combining CDC37 silencing with the HSP90 inhibitor 17-AAG induced more extensive and sustained depletion of kinase clients and potentiated cell cycle arrest and apoptosis. These results support an essential role for CDC37 in concert with HSP90 in maintaining oncogenic protein kinase clients and endorse the therapeutic potential of targeting CDC37 in cancer.
format Text
id pubmed-2635547
institution National Center for Biotechnology Information
language English
publishDate 2008
record_format MEDLINE/PubMed
spelling pubmed-26355472009-02-03 Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors Smith, Jennifer R. Clarke, Paul A. de Billy, Emmanuel Workman, Paul Oncogene Article The cochaperone CDC37 promotes association of HSP90 with the protein kinase subset of client proteins to maintain their stability and signalling functions. HSP90 inhibitors induce depletion of clients, which include several oncogenic kinases. We hypothesised that the targeting of CDC37 using siRNAs would compromise the maturation of these clients and increase the sensitivity of cancer cells to HSP90 inhibitors. Here we show that silencing of CDC37 in human colon cancer cells diminished association of kinase clients with HSP90 and reduced levels of the clients ERBB2, CRAF, CDK4 and CDK6, as well as phosphorylated AKT. CDC37 silencing promoted the proteasome-mediated degradation of kinase clients, suggesting a degradation pathway independent from HSP90 binding. Decreased cell signalling through kinase clients was also demonstrated by reduced phosphorylation of downstream substrates and colon cancer cell proliferation was subsequently reduced by inhibition of the G1/S-phase transition. Furthermore, combining CDC37 silencing with the HSP90 inhibitor 17-AAG induced more extensive and sustained depletion of kinase clients and potentiated cell cycle arrest and apoptosis. These results support an essential role for CDC37 in concert with HSP90 in maintaining oncogenic protein kinase clients and endorse the therapeutic potential of targeting CDC37 in cancer. 2008-10-20 2009-01-15 /pmc/articles/PMC2635547/ /pubmed/18931700 http://dx.doi.org/10.1038/onc.2008.380 Text en
spellingShingle Article
Smith, Jennifer R.
Clarke, Paul A.
de Billy, Emmanuel
Workman, Paul
Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors
title Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors
title_full Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors
title_fullStr Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors
title_full_unstemmed Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors
title_short Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors
title_sort silencing the cochaperone cdc37 destabilises kinase clients and sensitises cancer cells to hsp90 inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635547/
https://www.ncbi.nlm.nih.gov/pubmed/18931700
http://dx.doi.org/10.1038/onc.2008.380
work_keys_str_mv AT smithjenniferr silencingthecochaperonecdc37destabiliseskinaseclientsandsensitisescancercellstohsp90inhibitors
AT clarkepaula silencingthecochaperonecdc37destabiliseskinaseclientsandsensitisescancercellstohsp90inhibitors
AT debillyemmanuel silencingthecochaperonecdc37destabiliseskinaseclientsandsensitisescancercellstohsp90inhibitors
AT workmanpaul silencingthecochaperonecdc37destabiliseskinaseclientsandsensitisescancercellstohsp90inhibitors